Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19051044 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | February 2025 | September 2025 | Allow | 7 | 1 | 0 | No | No |
| 18979962 | LISINOPRIL FORMULATIONS | December 2024 | July 2025 | Allow | 7 | 2 | 0 | No | No |
| 18823257 | PHARMACEUTICAL COMPOSITION | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18823274 | PHARMACEUTICAL COMPOSITION | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18739646 | Safe Flavoring Composition to Improve Compliance in Colon Cleansing Compositions | June 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18663349 | LISINOPRIL FORMULATIONS | May 2024 | October 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18621397 | METHODS AND COMPOSITIONS FOR MANAGING PAIN COMPRISING DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | March 2024 | February 2026 | Abandon | 22 | 3 | 0 | No | No |
| 18600574 | COMPOSITIONS AND METHODS FOR HAIR TREATMENT | March 2024 | August 2025 | Allow | 17 | 4 | 1 | No | No |
| 18517529 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18496417 | Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking | October 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18381775 | COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGS | October 2023 | February 2025 | Abandon | 16 | 3 | 1 | Yes | No |
| 18484337 | PHARMACEUTICAL COMPOSITION | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18484334 | PHARMACEUTICAL COMPOSITION | October 2023 | November 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18457080 | NATURAL COMBINATION PRODUCTS AND METHODS FOR REGULATION OF KIDNEY AND EXCRETORY SYSTEM FUNCTION | August 2023 | December 2025 | Allow | 28 | 1 | 1 | No | No |
| 18450553 | LISINOPRIL FORMULATIONS | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18233560 | EMULSIONS FOR TREATING MUCOUS MEMBRANE INFECTIONS | August 2023 | April 2025 | Allow | 20 | 1 | 1 | No | No |
| 18229694 | Phosphodiesterase Inhibitor Treatment | August 2023 | February 2026 | Abandon | 31 | 3 | 1 | No | No |
| 18357004 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | July 2023 | March 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18356331 | CATHETER LOCK SOLUTION COMPRISING SODIUM CITRATE AND BENZYL ALCOHOL | July 2023 | December 2024 | Allow | 17 | 1 | 1 | No | No |
| 18223187 | LIPID-POLYMER COMPOSITIONS AND METHODS OF USE | July 2023 | November 2025 | Allow | 28 | 2 | 0 | No | No |
| 18353723 | NANOPARTICLE AND USE THEREOF FOR THE COMBINATORIAL THERAPY OF ENDOPLASMIC RETICULUM STRESS INDUCER AND IMMUNOTHERAPEUTIC TO TUMORS AND IMMUNE CELLS | July 2023 | March 2026 | Allow | 32 | 0 | 1 | No | No |
| 18222690 | BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS | July 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18331093 | COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATION | June 2023 | March 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18255675 | ORODISPERSIBLE POWDER COMPOSITION | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18035816 | PUNCTAL PLUGS CONTAINING MICELLE-ENCAPSULATED OPHTHALMIC PHARMACEUTICALS AND METHODS FOR MAKING THEREOF | May 2023 | January 2026 | Abandon | 32 | 0 | 1 | No | No |
| 18299444 | METHODS OF ALLEVIATING SYMPTOMS OF OCULAR SURFACE DISCOMFORT USING MEDICAL ICE SLURRY | April 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18129026 | Close-packed fibrous dosage form | March 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18189479 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND ANTI-IGM AGENTS | March 2023 | January 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18187165 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18123830 | SYSTEM AND METHOD FOR ALLERGEN-SPECIFIC EPICUTANEOUS IMMUNOTHERAPY | March 2023 | December 2025 | Allow | 33 | 1 | 1 | No | No |
| 18246005 | METHOD TO ENCAPSULATE AN AQUEOUS SOLUTION COMPRISING A COMPOUND OF INTEREST IN A MATRIX | March 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18043939 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | March 2023 | December 2025 | Abandon | 33 | 0 | 1 | No | No |
| 18043899 | C-PHYCOCYANIN FOR USE IN THE TREATMENT AND/OR PREVENTION OF PERIPHERAL NEUROPATHY | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18115029 | TREATMENT OF PRIMARY AND/OR SECONDARY LUNG TUMORS USING GASEOUS NITRIC OXIDE INHALATION | February 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18171007 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | February 2023 | November 2024 | Abandon | 21 | 3 | 0 | No | No |
| 18020544 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | February 2023 | August 2024 | Allow | 18 | 0 | 1 | No | No |
| 18020042 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18006083 | MOLYBDENUM-BASED FEED SUPPLEMENT FOR BEES | January 2023 | December 2025 | Allow | 35 | 1 | 1 | No | No |
| 18082826 | Base Composition for Tape Agent | December 2022 | March 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18080466 | TREATMENT OF MYOPIC PROGRESSION | December 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 17999920 | Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) | November 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17992348 | FORMULATIONS/COMPOSITIONS COMPRISING A BTK INHIBITOR | November 2022 | June 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17925234 | ZWITTERIONIC POLYMER PARTICLE COMPOSITIONS AND RELATED METHODS | November 2022 | October 2025 | Allow | 35 | 0 | 1 | No | No |
| 17922864 | DISSOLVABLE HYDROGEN PEROXIDE TEETH WHITENING STRIP OR FILM | November 2022 | February 2026 | Allow | 39 | 2 | 1 | Yes | No |
| 17947784 | SCALABLE POLYPROPIONATE LACTONE STEREOTETRADS | September 2022 | September 2025 | Allow | 35 | 1 | 0 | No | No |
| 17932736 | BIOMIMETIC VESICLES AND USES THEREOF | September 2022 | July 2024 | Allow | 22 | 0 | 1 | No | No |
| 17930373 | METHODS FOR DELIVERING AGENTS WITH PRE-FILLED SYRINGES TO MINIMIZE INTRAOCULAR INFLAMMATION | September 2022 | May 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17901108 | COMBINATION OF POLYETHYLENE GLYCOL AND RAPAMYCIN AND USE THEREOF | September 2022 | April 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17822922 | INTRAVENOUS FORMULATIONS OF RK-33 | August 2022 | November 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17898223 | COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKINCARE | August 2022 | July 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17896280 | LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES | August 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17815195 | SELF-ASSEMBLED NANOPARTICLE AND USE THEREOF FOR ANTI- ANGIOGENESIS | July 2022 | November 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17781314 | Adhesive Composition | May 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17664105 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | May 2022 | January 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17733210 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | April 2022 | December 2024 | Abandon | 32 | 4 | 0 | Yes | Yes |
| 17728382 | Metal Aluminum Nano-Adjuvant, Vaccine Composition And Preparation Method Therefor And Use Thereof | April 2022 | July 2024 | Allow | 27 | 1 | 1 | No | No |
| 17694821 | COMPOSITIONS FOR ALTERING THE COLOR OF HAIR | March 2022 | July 2025 | Abandon | 40 | 3 | 0 | Yes | No |
| 17653172 | BIODEGRADABLE NON-WOVEN FABRIC SHEET | March 2022 | January 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17668356 | STORAGE STABLE SOLUTION COMPRISING HYPOCHLOROUS ACID AND/OR HYPOCHLORITE | February 2022 | November 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17570548 | METHOD OF MANUFACTURING AN ORALLY DISINTIGRATING TABLET | January 2022 | May 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17616529 | METHOD FOR PREVENTING ADHESION OF ATMOSPHERIC TOXIC SUBSTANCE | December 2021 | December 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17533715 | COMPOSITIONS AND METHODS FOR INCREASED GLUCOSE UPTAKE AND FAT METABOLISM | November 2021 | January 2026 | Abandon | 50 | 2 | 1 | No | No |
| 17610389 | POLYMER-BASED IMPLANT FOR RETINAL THERAPY AND METHODS OF MAKING AND USING THE SAME | November 2021 | August 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17507733 | CHEWABLE TABLET | October 2021 | December 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17604691 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY ARRHYTHMIAS | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17497813 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST AIRBORNE PATHOGENS AND IRRITANTS | October 2021 | December 2025 | Allow | 50 | 4 | 1 | No | No |
| 17601409 | INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17488610 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | September 2021 | May 2025 | Abandon | 43 | 5 | 1 | No | Yes |
| 17437279 | PARTICLES WITH BIOCIDAL COATING | September 2021 | March 2025 | Allow | 42 | 1 | 1 | No | No |
| 17432579 | MEMBRANE | August 2021 | October 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17393745 | BIODEGRADABLE SHEET WITH ANTIVIRAL PROPERTIES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | August 2021 | April 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17387329 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF HUPERZINE AND METHODS OF USING THE SAME | July 2021 | January 2025 | Allow | 42 | 4 | 1 | No | Yes |
| 17417062 | AEROSOL FOAM DEVICE CONTAINING A COSMETIC COMPOSITION COMPRISING AN ANIONIC SURFACTANT, A FATTY ALCOHOL AND A COMPRESSED GAS | June 2021 | January 2026 | Abandon | 55 | 3 | 1 | No | No |
| 17323052 | LIPID-POLYMER COMPOSITIONS AND METHODS OF USE | May 2021 | November 2025 | Allow | 54 | 4 | 1 | No | No |
| 17322815 | Anti-Viral Lactoferrin Facemask | May 2021 | November 2024 | Abandon | 42 | 2 | 1 | Yes | No |
| 17294050 | NANOCRYSTALLINE EYE DROP, PREPARATION METHOD AND USE THEREOF | May 2021 | July 2025 | Abandon | 50 | 3 | 1 | No | No |
| 17289185 | BIS(TRIETHOXYSILYLPROPYL)AMINES COMBINED WITH POYSACCHARIDES FOR CARING FOR AND SHAPING KERATINE FIBRES | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17232336 | HYDROGEL PARTICLE CARRIERS FOR DELIVERY OF THERAPEUTIC/DIAGNOSTIC AGENTS | April 2021 | November 2024 | Abandon | 43 | 3 | 1 | No | No |
| 17231854 | POTENTIATED ANTIBIOTIC COMPOSITIONS AND METHODS OF USE FOR TREATING BACTERIAL INFECTIONS AND BIOFILMS | April 2021 | August 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17227978 | ORAL CARE COMPOSITIONS AND METHODS | April 2021 | November 2024 | Abandon | 43 | 7 | 1 | Yes | Yes |
| 17284097 | MACROCYCLIC LACTONE FORMULATIONS, METHODS OF THEIR PREPARATION AND USE OF THE FORMULATIONS IN TREATING PATHOLOGIES SECONDARY TO OPHTHALMIC PARASITES | April 2021 | November 2025 | Abandon | 55 | 3 | 1 | Yes | No |
| 17282703 | COMPOSITION COMPRISING NON-VOLATILE/VOLATILE OILS AND LIPOPHILIC DYES, METHODS AND USES THEREOF | April 2021 | January 2026 | Allow | 57 | 3 | 1 | No | No |
| 17200253 | OXYGENATED EMULSION FOR TREATMENT OF OCULAR INJURY | March 2021 | March 2026 | Abandon | 60 | 3 | 1 | No | Yes |
| 17193896 | HYPOTONIC HYDROGEL FORMULATIONS FOR ENHANCED TRANSPORT OF ACTIVE AGENTS AT MUCOSAL SURFACES | March 2021 | September 2025 | Abandon | 54 | 3 | 1 | Yes | No |
| 17172403 | OXYGENATED EMULSION FOR TREATMENT OF OCULAR INJURY | February 2021 | November 2025 | Abandon | 57 | 5 | 1 | No | No |
| 17266382 | ARTIFICIAL BONE AND MANUFACTURING METHOD OF ARTIFICIAL BONE | February 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17260073 | VE-PTP INHIBITION IN GLAUCOMA | January 2021 | March 2025 | Abandon | 50 | 2 | 1 | No | Yes |
| 17255200 | PROCESSING METHOD FOR DRUG SUBSTANCE PARTICLES OF NON-UNIFORM PARTICLE SIZE | December 2020 | December 2024 | Abandon | 48 | 4 | 1 | Yes | No |
| 17251247 | USE OF A BIXA ORELLANA EXTRACT | December 2020 | January 2026 | Abandon | 60 | 5 | 0 | Yes | No |
| 16973008 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17100495 | JAPANESE ENCEPHALITIS VACCINE-CONTAINING MICRONEEDLE ARRAY | November 2020 | January 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17091835 | INJECTABLE SILK FIBROIN PARTICLES AND USES THEREOF | November 2020 | October 2025 | Abandon | 59 | 2 | 0 | No | Yes |
| 17052694 | COMBINATION OF EXTRACTS OF QUINQUINA AND OF LEONTOPODIUM ALPINUM AND OF THE MANGANESE SALT OF L-PYRROLIDONE CARBOXYLIC ACID IN THE TREATMENT OF ALOPECIA | November 2020 | October 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17083386 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | October 2020 | December 2024 | Abandon | 49 | 4 | 1 | Yes | Yes |
| 16964198 | COMPOSITE SCAFFOLD MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2020 | November 2024 | Abandon | 52 | 2 | 1 | No | No |
| 17031841 | NANO EMULSION PROCESS FOR SCENTED LIQUIDS | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 15733458 | PROTECTING A BIOACTIVE AND/OR PRECURSOR THEREOF | July 2020 | June 2023 | Abandon | 35 | 6 | 1 | No | No |
| 16810149 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | March 2020 | July 2025 | Allow | 60 | 8 | 1 | No | No |
| 16608740 | ENCAPSULATED NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS | October 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16606506 | DRUG DELIVERY SYSTEM | October 2019 | February 2026 | Abandon | 60 | 3 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BASQUILL, SEAN M.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BASQUILL, SEAN M works in Art Unit 1614 and has examined 125 patent applications in our dataset. With an allowance rate of 70.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner BASQUILL, SEAN M's allowance rate of 70.4% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BASQUILL, SEAN M receive 2.68 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BASQUILL, SEAN M is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -5.1% benefit to allowance rate for applications examined by BASQUILL, SEAN M. This interview benefit is in the 5% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 15.1% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 26.1% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 53.8% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.8% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.